Osteosarcoma clinical trials

The registry lists 488 studies for Osteosarcoma across more than 10 countries. 124 are recruiting or about to start. 218 of them are mainly about Osteosarcoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its narrower condition Sarcoma, Ewing too: 622 studies, 155 open.

Get an email when these change. Save the Osteosarcoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 214
Recruiting: 101
Status unknown: 44
Terminated: 41
Active, not recruiting: 40
Not yet recruiting: 20

Phase

Phase 2: 216
Phase 1: 153
Phase 3: 21
Early Phase 1: 9
Phase 4: 2

Where

United States: 278
China: 60
Canada: 37
France: 36
Italy: 33
Puerto Rico: 25

Who runs them

National Cancer Institute (NCI) (54) · Children's Oncology Group (28) · Peking University People's Hospital (26) · Memorial Sloan Kettering Cancer Center (21) · St. Jude Children's Research Hospital (19) · M.D. Anderson Cancer Center (13) · Istituto Ortopedico Rizzoli (8) · Emory University (8)

What is being tested here

Drugs under test in Osteosarcoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Cabozantinib	5	2	10
Cyclophosphamide	3	0	13
Irinotecan	3	0	8
Doxorubicin	2	2	13
Methotrexate	2	2	10
Sirolimus	2	0	6
Zoledronic Acid	2	2	5
Fludarabine	2	0	4
Risvutatug rezetecan	2	1	3
Surufatinib	2	0	3

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 14 open · Antimetabolites 5 open · Immune checkpoint inhibitors 5 open · Alkylating agents 4 open · Angiogenesis inhibitors 3 open

Coming up

5phase 3 studies under way

44studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Nov 2026Musculoskeletal Cancers Remote Monitoring and Care · Case Comprehensive Cancer Center
Nov 2026Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma · Sun Yat-sen University
Dec 2026Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors · Bambino Gesù Hospital and Research Institute
Dec 2026A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma · Second Affiliated Hospital, School of Medicine, Zhejiang University
Dec 2026Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors · University of Wisconsin, Madison
Dec 2026Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors · South Plains Oncology Consortium
Dec 2026Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma · Emory University
Dec 2026Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas · Institut Bergonié
Dec 2026Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer · University Health Network, Toronto
Dec 2026ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma. · Hansoh BioMedical R&D Company

Who these studies take

Of the 101 Osteosarcoma studies recruiting now, 42 (42%) set no upper age limit and 55 (54%) stop at 75 or younger. 76 (75%) take children under 18. 1 (1%) are for women only and 0 (0%) for men only; 3 (3%) take healthy volunteers.

Recruiting studies that take each age, of 101
Age	Women	Men
10	52 (51%)	52 (51%)
18	98 (97%)	97 (96%)
30	87 (86%)	86 (85%)
40	76 (75%)	75 (74%)
50	66 (65%)	66 (65%)
65	60 (59%)	60 (59%)
75	53 (52%)	53 (52%)
85	44 (44%)	44 (44%)

Across all 488 studies, recruiting or not: 57% stop at 75 or younger and 51% at 65; 81% take children; <1% are for women only and <1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Osteosarcoma studies take

Of 76 phase 2 interventional studies under Osteosarcoma, half reached primary completion within 65 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	77 mo54–134 · 49 studies	—	—
Phase 1/2	77 mo40–92 · 33 studies	—	—
Phase 2	65 mo40–94 · 76 studies	—	66 mo41–94 · 72 studies
Interventional, no phase	53 mo14–114 · 22 studies	—	—
Observational	76 mo40–228 · 41 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 11, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 488. Browse all 488 → or search them.